WHY JOIN?
What you get as a PAN member
First look at deals
DAN members get early access to investment opportunities at preferred terms before general offerings open.
Emerging tech newsletter
Curated insights on digital health, biosensing, AI/wellness convergence written for clinicians who want signal over noise.
Shape what gets built
Your clinical perspective directly informs technology decisions. You're not advising after the fact, you're in it early.
Peer network
Connect with physicians across specialties who are engaged in healthcare innovation. Virtual and in-person events.
Sign up to become a member today.
TECHNOLOGY PIPELINE
Our portfolio is bigger than you think.
We scored 130 technologies and narrowed to 20 active candidates. These are the most advanced. Each represents a defined market, a viable FDA pathway, and a known buyer landscape.
Healthcare IP · 30-Month Development · Exit-Ready
-
Acquire healthcare IP from universities, hospital groups, and physicians
-
Develop each technology through engineering, FDA compliance, and beta testing
-
License or sell to strategic buyers. Every technology is built to be acquired
-
AI-driven vetting identifies the best technologies and buyers before we invest a dollar
-
Each technology funded through its own SPV; capital efficient, focused, exit-ready
REQUEST INVESTOR ACCESS
No spam. Materials sent within one business day. Confidential.
PHYSICIAN ADVISORY NETWORK
Clinical insight built into every program.
-
Practicing physicians and specialists across relevant clinical disciplines
-
Led by a designated Head of Doctors Network
-
Engaged at concept validation, development, and commercialization; not just at the end
-
Provides real-world clinical needs assessment and regulatory pathway input
-
Strengthens adoption among peers, payers, and health systems at exit
-
Members may also participate as qualified investors, bringing capital and credibility
Safe Harbor Statement & Important Disclosures. This page and any materials made available through it contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied. This page does not constitute an offer to sell or a solicitation of an offer to purchase any security. Any offering of securities will be made only by means of definitive offering documents and only to qualified investors. An investment in Promptus or any related special purpose vehicle involves a high degree of risk, including the possible loss of the entire amount invested. Past performance of any technology, portfolio company, or team member is not indicative of future results. Promptus is offering securities pursuant to an exemption from registration under Regulation D of the Securities Act of 1933, as amended. This offering has not been registered with the SEC or any state securities regulator. Prospective investors should conduct their own due diligence and consult with their own legal, tax, and financial advisors prior to making any investment decision. Pipeline technologies are in varying stages of development; some technologies may not reach commercialization. Market size estimates are based on publicly available third-party data and internal analysis and are subject to change.
Shape the future of healthcare technology.
Healthcare technology gets built by engineers, approved by regulators, and used by you — usually in that order. We're changing the sequence.